Loading...

뉴스 목록

Merck's new HIV drug Pedro (Doravirin) was approved in China

2020-12-08


Merck's new HIV drug Pedro (Doravirin) was approved in China

Merck announced recently that its new HIV drug Pedro (doravirin tablets) has been officially approved by the NMPA for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults. This approval is based on a global phase III pivotal, randomized, multi-center, double-blind, active drug controlled clinical trial code-named DRIVE-FORWARD, which aims to evaluate the effect of dolavirin on patients without previous antiretroviral therapy Efficacy and safety of people infected with HIV-1.


The DRIVE-FORWARD trial reached its primary clinical endpoint. The data of the 48th and 96th weeks both showed that compared with the control group darunavir-ritonavir (DRV/r), it was at the same time with emtricitabine (FTC)/tenofovir disoproxil In the combination of ester (TDF) or abacavir (ABC)/lamivudine (3TC), doravirine (DOR) showed non-inferiority.


At the same time, the data from the DRIVE-FORWARD Phase III trial also showed significant clinical benefits for patient weight and blood lipid control.


당사는 귀하의 웹사이트 이용을 더 잘 이해하기 위해 쿠키를 사용하고자 하며, 이는 향후 웹사이트 방문 시 귀하의 경험을 개선하는 데 도움이 될 것입니다. 브라우저 설정에서 이 설정을 변경할 수 있습니다. 쿠키 사용에 대한 자세한 내용은 개인정보 보호정책을 참조하세요.